2
|
Joly F, Bourgeois H, Floquet A, Chinet-Charrot P, Meyer F, Lebrun D, Hamond K, Leroy C, Heron JF. Efficacy and tolerability of the ifosfamide-epirubicin combination in relapsed ovarian cancer. Int J Gynecol Cancer 2006; 16:77-82. [PMID: 16445614 DOI: 10.1111/j.1525-1438.2006.00288.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
A retrospective study evaluating the efficacy and tolerability of epirubicin-ifosfamide (EI) in patients with relapsed advanced ovarian cancer (ROC) after prior chemotherapy was conducted. A total of 93 patients received epirubicin (50 mg/m(2), day 1), ifosfamide (1500 or 2500 mg/m(2), days 1-3), and mesna monthly. Thirty-five percent had received one line of chemotherapy (platinum 100%, taxanes 8%); 38%, two lines; and 27%, more than two lines. Fifty-three percent received 2500 mg/m(2)/day ifosfamide and 47% received 1500 mg/m(2)/day ifosfamide. Ifosfamide was administered by continuous infusion in 12 patients. Mean number of courses was 4 (1-12). Grade 4 toxicity was 69% neutropenia and 12% thrombocytopenia. Three patients on high-dose ifosfamide as a short infusion had central nervous system dysfunction resulting in death. There were 84 assessable patients: 7 (8%), complete responses; 13 (15%), partial responses; and 20 (24%), stable disease. Median time to progression was 5 months (3 days to 36 months). The EI combination appears to be effective in ROC. However, toxicity with high-dose ifosfamide administered by short infusion is not acceptable. Tolerability can be improved using ifosfamide at 1500 mg/m(2) by continuous infusion. The combination of ifosfamide with newer anthracycline agents such as liposomal doxorubicin may be an alternative and needs further evaluation for use after first-line taxane-based chemotherapy.
Collapse
Affiliation(s)
- F Joly
- Medical Oncology Department, Centre de Lutte contre le Cancer Francois Baclesse, Route de Lion sur Mer, BP 5026, 14076 Caen Cedex 05, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Chinet-Charrot P, Joly F, Bourgeois H, Lortholary A, Leduc B, Priou F, Cumin I, Sevin E, Hamond K, Henry-Amar M. Association of pegylated liposomal doxorubicin (PLD) and ifosfamide (IFO) in early recurrent ovarian cancer patients: A multicenter phase II trial. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.5043] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- P. Chinet-Charrot
- Ctr Henri Becquerel, Rouen, France; Ctr François Baclesse, Caen, France; Ctr Hospitalo-universitaire, Tours, France; Ctr Paul Papin, Angers, France; Ctr Hospitalier, Brives, France; Ctr Hospitalier, La Roche sur Yon, France; Ctr Hospitalier, Lorient, France
| | - F. Joly
- Ctr Henri Becquerel, Rouen, France; Ctr François Baclesse, Caen, France; Ctr Hospitalo-universitaire, Tours, France; Ctr Paul Papin, Angers, France; Ctr Hospitalier, Brives, France; Ctr Hospitalier, La Roche sur Yon, France; Ctr Hospitalier, Lorient, France
| | - H. Bourgeois
- Ctr Henri Becquerel, Rouen, France; Ctr François Baclesse, Caen, France; Ctr Hospitalo-universitaire, Tours, France; Ctr Paul Papin, Angers, France; Ctr Hospitalier, Brives, France; Ctr Hospitalier, La Roche sur Yon, France; Ctr Hospitalier, Lorient, France
| | - A. Lortholary
- Ctr Henri Becquerel, Rouen, France; Ctr François Baclesse, Caen, France; Ctr Hospitalo-universitaire, Tours, France; Ctr Paul Papin, Angers, France; Ctr Hospitalier, Brives, France; Ctr Hospitalier, La Roche sur Yon, France; Ctr Hospitalier, Lorient, France
| | - B. Leduc
- Ctr Henri Becquerel, Rouen, France; Ctr François Baclesse, Caen, France; Ctr Hospitalo-universitaire, Tours, France; Ctr Paul Papin, Angers, France; Ctr Hospitalier, Brives, France; Ctr Hospitalier, La Roche sur Yon, France; Ctr Hospitalier, Lorient, France
| | - F. Priou
- Ctr Henri Becquerel, Rouen, France; Ctr François Baclesse, Caen, France; Ctr Hospitalo-universitaire, Tours, France; Ctr Paul Papin, Angers, France; Ctr Hospitalier, Brives, France; Ctr Hospitalier, La Roche sur Yon, France; Ctr Hospitalier, Lorient, France
| | - I. Cumin
- Ctr Henri Becquerel, Rouen, France; Ctr François Baclesse, Caen, France; Ctr Hospitalo-universitaire, Tours, France; Ctr Paul Papin, Angers, France; Ctr Hospitalier, Brives, France; Ctr Hospitalier, La Roche sur Yon, France; Ctr Hospitalier, Lorient, France
| | - E. Sevin
- Ctr Henri Becquerel, Rouen, France; Ctr François Baclesse, Caen, France; Ctr Hospitalo-universitaire, Tours, France; Ctr Paul Papin, Angers, France; Ctr Hospitalier, Brives, France; Ctr Hospitalier, La Roche sur Yon, France; Ctr Hospitalier, Lorient, France
| | - K. Hamond
- Ctr Henri Becquerel, Rouen, France; Ctr François Baclesse, Caen, France; Ctr Hospitalo-universitaire, Tours, France; Ctr Paul Papin, Angers, France; Ctr Hospitalier, Brives, France; Ctr Hospitalier, La Roche sur Yon, France; Ctr Hospitalier, Lorient, France
| | - M. Henry-Amar
- Ctr Henri Becquerel, Rouen, France; Ctr François Baclesse, Caen, France; Ctr Hospitalo-universitaire, Tours, France; Ctr Paul Papin, Angers, France; Ctr Hospitalier, Brives, France; Ctr Hospitalier, La Roche sur Yon, France; Ctr Hospitalier, Lorient, France
| |
Collapse
|